(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 19.89% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Guardant Health's revenue in 2025 is $739,016,000.On average, 9 Wall Street analysts forecast GH's revenue for 2025 to be $105,541,129,999, with the lowest GH revenue forecast at $103,970,221,898, and the highest GH revenue forecast at $106,882,967,906. On average, 9 Wall Street analysts forecast GH's revenue for 2026 to be $128,339,291,738, with the lowest GH revenue forecast at $125,174,025,462, and the highest GH revenue forecast at $134,071,477,144.
In 2027, GH is forecast to generate $161,162,730,286 in revenue, with the lowest revenue forecast at $149,446,086,049 and the highest revenue forecast at $177,717,001,325.